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Neuroblastoma serves as a paradigm for applying tumor genomic data for determining
patient prognosis and thus for treatment allocation. MYCN status, i.e., amplified vs. non-
amplified, was one of the very first biomarkers in oncology to discriminate aggressive
from less aggressive or even favorable clinical courses of neuroblastoma. However, MYCN
amplification is by far not the only genetic change associated with unfavorable clinical
courses. So called “segmental chromosomal aberrations,” (SCAs) i.e., gains or losses of
chromosomal fragments, can also indicate tumor aggressiveness.The clinical use of these
genomic aberrations has, however, been hampered for many years by methodical and
interpretational problems. Only after reaching worldwide consensus on markers, method-
ology, and data interpretation, information on SCAs has recently been implemented in
clinical studies. Now, a number of collaborative studies within COG, GPOH, and SIOPEN
use genomic information to stratify therapy for patients with localized and metastatic dis-
ease. Recently, new types of DNA based aberrations influencing the clinical behavior of
neuroblastomas have been described. Deletions or mutations of genes like ATRX and a
phenomenon referred to as “chromothripsis” are all assumed to correlate with an unfavor-
able clinical behavior. However, these genomic aberrations need to be scrutinized in larger
studies applying the most appropriate techniques. Single nucleotide polymorphism arrays
have proven successful in deciphering genomic aberrations of cancer cells; these tech-
niques, however, are usually not applied in the daily routine. Here, we present an ultra-high
density (UHD) SNParray technique which is, because of its high specificity and sensitivity
and the combined copy number and allele information, highly appropriate for the genomic
diagnosis of neuroblastoma and other malignancies.
Keywords: SNParray, neuroblastoma, genomic, genetic risk factors, amplification, chromothripsis, precision
medicine, INRG
INTRODUCTION
Precision medicine aims to adjust the therapy of cancer patients
according to the predicted biological behavior and/or genomic
profile of the individual tumor, which can be assessed by dif-
ferent methods. The use of biomarkers is especially important
for neuroblastoma patients, as the clinical and biological behav-
ior may vary drastically. A subset of neuroblastic tumors will
undergo spontaneous regression (especially in infants) or spon-
taneous maturation (in children), whereas other neuroblastomas
will rapidly progress despite intensive multimodal therapy. This
clinical heterogeneity has been common knowledge for decades
(1–4), and for many years only age and tumor stage (currently
the disease is divided into localized stages: L1 and L2, depending
on the resectability, and disseminated stages: M and MS, the lat-
ter representing the former 4S stage (5)) were used to categorize
neuroblastoma patients. However, in most cases this information
alone cannot reliably predict tumor behavior. Over the past three
decades, tumor histology (6, 7), status of the MYCN oncogene (8,
9), and tumor cell DNA content (ploidy) (10, 11) have each been
shown to be independently predictive of patient outcome in large
retrospective and prospective studies. Besides these two genomic
markers, also a number of segmental chromosomal aberrations
(SCAs), affecting different chromosomes, have been described and
it is now assumed that, besides MYCN amplification, the presence
of these aberrations does also have a strong effect on the tumor
cells, rendering them more aggressive and/or therapy-refractory
(12–14). However, recent data indicate that the overall survival
(OS) is not influenced by the presence of SCAs in patients below
18 months with localized resectable, not MYCN amplified dis-
ease. On the other hand, SCAs are associated with unfavorable OS
in >18 months patients with the same clinical feature (Ambros
et al., personal observation). Here, we present a brief overview
of the DNA based biomarkers described in neuroblastoma and
briefly touch upon the standardized operating procedures (SOPs)
formalized by the biology subcommittee of the International Neu-
roblastoma Risk Group (INRG) for performing neuroblastoma
tumor molecular diagnostics (15).
Moreover, a recent paper by Pugh and co-workers, summa-
rizing a large number of sequence data, indicates a low median
exonic mutation frequency and only few recurrently mutated
genes. Among these, ALK was most frequently affected (9.2%);
all other genes were found to be mutated in less than 3%:
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PTPN11, 2.9%; ATRX, 2.5%; MYCN, 1.7%; NRAS, 0.83% (16).
This study was completed by the findings of ARID1A and ARID1B
mutations/deletion in 11% of analyzed tumors (17).
In tune with current development, we will focus mainly on the
use of an ultra-high density (UHD) single nucleotide polymor-
phism array (SNParray) technique for the molecular diagnostic
work up of neuroblastic tumors. So far only very few studies
applied SNParray techniques in the diagnostic work up of neurob-
lastomas. The first reports on SNP array data of neuroblastoma
tumors were done by an American and a British group both in
2007 (18, 19). George and co-workers described a high concor-
dance between 1p, 3p, and 11q deletion and LOH and reported
on copy neutral LOH (cnLOH) at the short arm of chromosomal
arm 11p. The Newcastle group correlated SNP array data with
expression data. In 2011, Kryh and co-workers using a SNP array,
found cnLOH as a frequent event in neuroblastoma cell lines (20).
Souzaki et al. reported in their SNP array study on a significantly
higher number of SCAs in older patients and a possible correla-
tion of the number of SCAs and outcome in diploid/tetraploid
neuroblastomas without MNA, however no, information on LOH
data was given (21).
To learn about the applicability of an UHD genome-wide SNP
array technology in the diagnostic work up of neuroblastomas,
we introduced a SNP array platform (CytoScan® HD Array) in
our laboratory in 2012. This pan-genomic technique increased
the diagnostic yield enormously in comparison to the hith-
erto limited but nevertheless useful multilocus (neuroblastoma-
specific) MLPA technique and the single loci interphase FISH
(I-FISH) investigations. The latter, in fact, will probably not
become obsolete owing to its very specific advantages, i.e., the
analysis of single cells, the possibility to investigate tumor sam-
ples with low tumor cell contents and with intratumoral het-
erogeneities, especially in case of oncogene amplifications. In
addition, I-FISH results provide information on the somy level
of the target chromosome, thus help to define the base line in
array studies of aneuploid tumors, especially in complex mosaic
situations.
Since 2012, we retrospectively and prospectively worked off a
large number of neuroblastoma samples and performed SNP data
analysis and interpretation by the ChAS software or, for compar-
ison of larger number of tumor samples, by the Nexus software.
The individual SNP profiles were compared and validated with
available FISH and MLPA results.
RESULTS
VISUALIZING THE WHOLE TUMOR GENOME
Although in the daily routine work, the single chromosome
genome analysis – as it is done, e.g., by the ChAS software (for
details see Materials and Methods section and Supplementary
Materials) – is indispensable, we start our introduction into UHD
SNP array analysis with a whole genome visualization. One way
to present all genomic changes in one graph is to use the so called
Circos plots. This type of visualization tool allows the identifica-
tion of copy number changes at one glance. In the different Circos
plots presented in this paper (Figures 1, 2, 6, and 7 and Figure S2 in
Supplementary Material), the following information is provided:
the chromosome ideograms with the Mb information are located
along the outside of the diagram. It is followed inwards by the
copy number probe track and the allele frequency track. In case
there are whole chromosome/segmental gains or losses, the copy
number track is labeled in the usual color code, i.e., blue color
indicates gain or amplification of chromosomal material and red
indicates loss of material.
In Figure 1, SNParray results from normal cells, which occur
and expand during the maturation process of neuroblastoma,
i.e., from the ganglioneuroblastoma/ganglioneuroma-associated
Schwann cells, are presented in a Circos plot. All autosomes clearly
show three single tracks in the allele peak circle as it is expected for
normal cells. The allele peak tracks consist of single points, each
of which representing a single SNP interrogated by “A” and “B”
allele probes. Thus, the three tracks reflect the allele combination
AA, AB, and BB, which is in line, together with the copy number
information, with a disomy of all chromosomes with the exception
of the X and the Y chromosomes, which are present in one copy
each, reflected by only two allele peak tracks (allele distribution:
AA, BB) and the red labeled copy number tracks. In contrast to
the neuroblastoma-associated Schwann cells, neuroblastoma cells
with differentiation capacity and with ganglionic differentiation
usually show numeric (whole) chromosome aberrations as given
in the Circos plot of Figure 2 and the FISH picture and the single
chromosome view in Figure 3.
Due to the design of a Circos plot,only a condensed form of data
can be presented. For detailed analyses, as shown in Figures 3–5
and 8–10 (and Figure S1 in Supplementary Material), SNPar-
ray data are given in single chromosome (complete or detail)
views. The data in this detailed graphical visualization accord-
ing to the ChAS software are arranged differently as compared to
the Circos plot. The cytoband information at the bottom of the
graph is followed by the gene annotations (red bars) in the next
track. In this lower field of the detailed view, the software also
allows for the visualization of information which is not shown in
this presentation. Most importantly, the copy number variations
(CNVs) with the corresponding annotations can be shown for
every genomic locus, thus helping to better interpret microdele-
tions and -gains (Figure S1 in Supplementary Material). The next
track in Figures 3–5, 8 and 10, represented by a line, indicates the
so called “smooth signal” – the underlying algorithm performs a
smoothing of the copy number information thus providing help-
ful, albeit sometimes crude, information on the copy number state
of the chromosome or parts thereof. This information in combi-
nation with the log2 information and, importantly, together with
the allele frequency data, allows a detailed identification of the
underlying genomic changes.
The visualization of the whole genome from a near-triploid
tumor presented in form of a Circos plot is shown in Figure 2.
Ten autosomes show gains of whole chromosomes resulting in a
trisomic state, chromosome 17 is tetrasomic and all other auto-
somes are disomic. In Figure 3B, a close up single chromosome
view shows a trisomy 2. The whole chromosome gain is discernible
by a copy number state above 2.0 (Figure 3B, see smooth signal;
concerning “baseline problems” see below and figure legend) and,
importantly, also by the allele frequency which indicates the exact
somy status. The allele track (the middle track in Figure 3B) shows
four single tracks representing the “allele distribution” AAA, AAB,
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FIGURE 1 | Circos plot showing the normal chromosomal
complement from a Schwann cell dominant tumor. The outer ring
indicates the chromosome ideograms and distances in Mb. The next ring
indicates the copy number information. All autosomes are disomic (black
dots), the X and Y chromosomes are present in one copy each (red dots).
The innermost ring represents the allele peak frequency of the
chromosomes. All autosomes disclose three allele peak tracks whereas
the X and Y chromosomes show only two tracks; exception: the
pseudo-autosomal regions on the tips of the X chromosome, which have
three allele tracks.
BBA, and BBB which is in line with a trisomy. The equal spacing
between the tracks points to a pure trisomic population, thus indi-
cates a baseline“error”(see below). A FISH image of differentiating
neuroblast nuclei is shown in Figure 3A applying chromosome 2
subtelomeric and a MYCN specific probe. A trisomy 2 is reflected
by the hybridization pattern with three pairs of signals per nucleus
in the majority of nuclei. Occasional nuclei with a hexasomy 2, as
shown in the picture, are not uncommon.
“HIGH” COPY NUMBER ABERRATIONS – AMPLIFICATIONS
Interphase FISH used for the detection of gene amplifications
can be considered as classical diagnostic tool for such purposes,
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FIGURE 2 | Circos plot of a near-triploid neuroblastoma. Chromosomes 1,
2, 5, 6, 7, 12, 13, 16, 18, and 22 are trisomic, represented by the blue dots in
the copy number track and four tracks each for the allele peaks. Note that
chromosome 17, despite showing three allele peak tracks, is not disomic but
tetrasomic, as can be seen by the blue copy number dots. All other
autosomes are disomic.
as it is a quick and reliable technique and allows analyses at
the single cell level. As seen in Figure 4A, the number of FISH
spots varies markedly from cell to cell, ranging from hundreds
per nucleus to a small excess of signals in comparison to the
reference probe (in red) located on the short arm of chromo-
some 2. This variation is caused by the random distribution of
double minute chromosomes (dmin) to the daughter cells dur-
ing cell divisions. Despite this unequal dmin distribution among
the different cells, we call this a homogeneously amplified tumor,
since virtually all tumor cells show supernumerary MYCN sig-
nals, with a mostly more than four-fold increase in the MYCN
signal number compared to the reference probe (thus being
well above the threshold value as it was defined for neuroblas-
toma diagnostics). Array based techniques, as well, show distinct
peaks, surpassing by far the four times ratio of the fluorescence
intensities.
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FIGURE 3 |The FISH picture in (A) highlights three nuclei
co-hybridized with MYCN and 2p specific probes. Both probes,
MYCN (green) and the reference probe (red), are present in a balanced
manner – either 3 pairs or 6 pairs in the upper cell. (B) The SNP array
profile for chromosome 2. Copy number probe intensities (log2 ratio)
are represented in the upper track. The four allele peak tracks in the
middle indicate a trisomic situation due to the allele distribution AAA,
AAB, ABB, and BBB. The smooth signal above the ideogram is
between 2 and 3 because of difficulties in base line adjustment in
cases of triploid tumors.
The detailed SNParray data from one MYCN amplified tumor
are visualized in Figure 4B. The signal intensities of the different
genes that are contained in the amplicons (i.e., an amplification
unit that can consist of one or more genes) reach copy number
values of up to ~48. The amplicon contains the full lengths of the
MYCN gene, the DDX1, and part of the NBAS gene.
The complete genomic picture of a MYCN amplified tumor as
presented in Figure 4A is visualized in the Circos plots shown in
Figure S2 in Supplementary Material. The Circos plot shows only
very few SCAs, i.e., loss of 1p and gain of 17q.
Besides the more frequently found “classical,” i.e., homoge-
neous,MYCN amplification, neuroblastomas can also show intra-
tumoral heterogeneity for the MYCN status, clearly detectable by
the use of FISH techniques, which allow the identification of sin-
gle cells. In these tumors, various proportions of tumor cells with
amplification (and gain) of this gene and tumor cells without
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FIGURE 4 | Depicts examples of homogenous “classical” and
heterogeneous MYCN amplified tumors. The FISH picture, (A) (MYCN
FISH probe in green, 2p probe in red), shows tumor cell nuclei with a
varying number of MYCN signals ranging from approximately 30 signals
up to hundreds distributed randomly within the nuclei. The large size of
some of the MYCN hybridization spots can be explained by repeated
amplicon units. The SNParray profile of a segment of the short arm of
chromosome 2 from a homogeneously amplified neuroblastoma is given
in (B) which shows a clear peak for the MYCN locus (copy number ~48).
(C,D) Examples of a so called hetMNA tumor. In the I-FISH picture
(C), one tumor cell nucleus clearly displays MYCN amplification (arrow),
while the others do have a balanced number of MYCN and reference
probe hybridization signals. The SNParray profile (D) shows an example
of a heterogeneous MYCN amplified tumor with much lower peaks (copy
number<3 of the smooth signals, lower line) than compared to the
profile given in (B) and could easily be missed if the number of tumor cell
nuclei with MYCN amplification is too small in the sample under
examination.
this aberration – yet unambiguously identifiable as tumor cells –
coexist (Figure 4C). For identifying intratumoral heterogeneity of
MYCN amplification, FISH is the method of choice, since rou-
tinely applied array techniques are based on the DNA extracted
from a large number of cells and not on the visualization of single
cells. The amplification will be visible only if the number of ampli-
fied cells in the sample and the degree of amplification surpasses
a certain threshold. This holds also true for the UHD SNParray
even if its sensitivity is very high. If a subclone of amplified cells is
detected, the amplicon is mostly only visible as a gain. A ChAS gen-
erated image of a tumor area with only a minority of tumor cells
disclosing the amplification is shown in Figure 4D. The log2 ratios
of this SNParray sample correspond to roughly three copies. The
SNParray pattern of a gain of the short arm of chromosome 2 or
of parts thereof differs from the pattern of a heterogeneous ampli-
fication regarding the size of the gained region, which markedly
exceeds the amplicon size, i.e., the MYCN gene and its adjacent
genes or loci.
However, in neuroblastoma tumors, not only MYCN and
adjacent genes can be affected by an amplification process,
but also ALK (see below and Discussion section) and other
genes/loci on chromosome 2 (not shown). Furthermore, the
chromosome 12q arm contains other – in neuroblastoma not
infrequently amplified – genes, among them oncogenes and cell
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FIGURE 5 |The copy number data disclose a high number of amplicons
on the long arm of chromosome 12. The log2 copy number track and the
smooth signal track show a number of copy number peaks ranging from ~10
to ~42 copies. The different amplicons contain the following genes MDM2,
MDM1, CDK4, DCD, INHBC, GLI1, OS9, METTL1, RSSFJ, GNS, MSRB3, and
IL26 besides a number of other ones.
cycle-associated genes (MDM2, CDK4, OS9, and GLI1, see
Figure 5).
“LOW” COPY NUMBER ABERRATIONS – SEGMENTAL GAINS AND
LOSSES
Segmental chromosomal aberrations, defined as gains or losses of
larger chromosomal regions, are hallmarks of most aggressive neu-
roblastomas. Losses of total chromosomal arms or parts thereof
are frequently associated with loss of heterozygosity (LOH) of the
affected chromosomal region. Chromosome arms 1p and 11q are
most frequently involved in these processes (Figure 6 and Figure
S2 in Supplementary Material). These two aberrations are part of
seven recurrent segmental gains and losses currently regarded as
prognostically meaningful or “‘typical” SCAs (i.e., losses at 1p, 3p,
4p, and 11q and gains at 1q, 2p, and 17q). All other segmental
aberrations are presently called atypical SCAs. The Circos plot in
Figure 6 shows a typical deletion at the long arm of chromosome
11 (11q13.4-qter). The copy number changes from two copies to
one copy is represented by the red labeled dots and is accompanied
by the loss of allelic probes resulting in the appearance of only two
allele probe tracks reflecting the A and B status of this region. The
non-affected part of the chromosome pair shows both the normal
copy number pattern and the typical three allele tracks. Especially
in mosaic situations, the additional allele information can be of
great help to unambiguously identify copy number changes.
MULTIPLE SEGMENTAL GAINS AND/OR LOSSES WITHIN CONFINED
REGIONS OF THE GENOME – CHROMOTHRIPSIS
An example of chromothripsis affecting the whole chromosome
2 is shown in Figures 7 and 8. The Circos plot of this tumor
already indicates a large number of aberrations in this chromo-
some and the detailed view done with the ChAS software allows
a precise annotation of the breakpoints along the chromosome.
In addition, this tumor shows a MYCN as well as an ALK ampli-
fication (Figure 8). In case of chromothripsis, the copy number
changes typically oscillate between gains or losses of one and two
copies visible in the copy number state and the SNP profile. So
far, we have detected chromothripsis in 4.3% of neuroblastomas
(10 out of 233 evaluable tumors, all stages). These patients with
chromothripsis tumors had predominantly high stage tumors. In
three tumors, this aberration was associated with amplification of
the MYCN gene, one had a heterogeneous MNA and the others
were not amplified.
ALTERATIONS OF SINGLE GENES – INTRAGENIC GAINS AND LOSSES
Figure 9 shows the X chromosome with a close up highlighting
the ATRX gene located in the cytoband Xq21.1. In the upper part
of the Figure 9, the copy number probes show a clear deletion
spanning from exon 2 to exon 8. In the lower part of the figure,
five examples of ATRX gene deletions are given. Among the 213
evaluable samples analyzed in this study, an intragenic deletion of
the ATRX gene was found in 21 tumors (9.9%). All ATRX deleted
tumors also showed the ALT phenotype (alternative lengthening
of telomeres) that is typical for the loss of the ATRX gene function
(data not shown).
COPY NEUTRAL VARIATIONS – UNIPARENTAL WHOLE CHROMOSOME
AND SEGMENTAL LOHes
In case of deletions of whole chromosomes or parts thereof,
which are associated with LOHes, a two track SNP probe pat-
tern is visible as shown in Figure 6. However, the typical LOH
SNP pattern is not only found in combination with copy number
changes but can also occur without losses, i.e., in copy neutral sit-
uations. In case the LOHes concern a whole chromosome, they are
called UPD (uniparental isotrisomies and isotetrasomies can also
occur). In case of segmental UPDs, only parts of a chromosome
www.frontiersin.org August 2014 | Volume 4 | Article 202 | 7
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FIGURE 6 | A Circos plot of chromosome 11q deleted neuroblastoma. The
red track in the log2 copy number lane already indicates the loss of genomic
material. The two allele peak tracks indicate LOH. In addition, the short arms
of chromosomes 3 and 4 and the long arm of chromosome 16 show deletions
accompanied by LOHes. The chromosome 9 shows a whole chromosome
UPD and a 9p21.3 loss resulting in a nullisomy for the genes CDKN2A and 2B.
Further segmental aberrations were found on chromosomes 14 and 17.
A whole chromosome gain was found for chromosome 7.
are concerned (also called: ROH, runs of homozygosity or LCSH,
long contiguous stretches of homozygosity). Figure 10 shows a
whole chromosome UPD of chromosome 11 in a L2 neuroblas-
toma without MNA. These aberrations, especially the segmental
UPDs can either be constitutional or somatic, i.e., tumor specific.
Clarification by analysis of reference DNA is frequently necessary
for a final assignment of the aberration to the exact category.
DISCUSSION
CHANCES AND LIMITS OF SINGLE NUCLEOTIDE POLYMORPHISM
PROBE ANALYSES USED IN TUMOR DIAGNOSTICS
In cancer research, the great value of genome-wide SNP arrays is
constituted by the combined information of copy number changes
and allele status by SNPs in pure and mosaic situations. The
Affymetrix UHD SNP array (CytoScan® HD Array) contains more
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FIGURE 7 | An example of the recently described “chromothripsis.” As visualized by the Circos plot, only chromosome 2 but no other chromosome showed
structural aberrations. However, the concerned chromosome underwent extreme shattering and reshuffling, as detailed in Figure 8.
than 1.9 million non-polymorphic markers and over 740,000 SNP
markers with an average intragenic marker spacing of 880 bps and
intergenic marker spacing of 1737 bps. The high non-polymorphic
marker coverage guarantees the reliable detection of copy num-
ber changes (variations and alterations, see below) even in the
range of microdeletions or microgains, i.e., small deletions/gains
in non-coding regions/genes and even in single introns or exons
(dependent on the coverage of the concerned region, see for
example the ATRX gene section and Figure 9). The combina-
tion of copy number with the allele information, i.e., the zygosity
status, enables the detection of LOHes with copy losses as well
as copy neutral allelic changes. In addition, the UHD SNP array
has a high sensitivity for mosaicism detection, which, in the lit-
erature, is associated with a detection limit for mosaicism of less
than 5% (22). The limits of the technique concern translocations.
In case they are balanced, without gains or losses of sequences,
www.frontiersin.org August 2014 | Volume 4 | Article 202 | 9
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ambros et al. SNParray in neuroblastoma molecular diagnostics
FIGURE 8 | A detailed view of the genomic features of the
chromothripsis case described in Figure 7. The chromothripsis with 60
breakpoints lying in both chromosomal arms (chromosome 2) lead to a large
number of copy number variations represented in an oscillating copy number
profile (visible in all tracks). In addition, the profile shows two amplicons
including MYCN and ALK besides other genes (highlighted by asterisks).
they are not detectable by this technique. If gains or losses occur
next to known translocation breakpoints, the presence of such
alterations, i.e., gene rearrangements, can be deduced indirectly in
a portion of rearranged tumors (23). The only technique which
can overcome this problem, also in cases of unknown or unex-
pected translocations, is whole genome sequencing. FISH is help-
ful and of diagnostic value only in cases of known and suspected
translocations for which FISH probes exist. In neuroblastoma,
however, balanced translocations are described to represent only
very infrequent events.
A so far unsolved software problem concerns the normaliza-
tion of the copy number information, i.e., the calculation of the
“baseline.” In case of aneuploid DNA contents, the ChAS (as well
as the Nexus) software is often not able to calculate the correct
monosomic or disomic levels, i.e., the “baseline.” This is, how-
ever, crucial in order to discriminate, e.g., odd number of (whole
or segmental) chromosomal gains from mosaics with LOHes,
which both end up with four allele tracks. After correct base-
line assessment, “absolute” chromosome numbers can easily be
determined.
INDIVIDUAL VARIANTS – THE COPY NUMBER VARIATIONS
Since UHD SNP arrays are able to capture even micro-alterations,
we have to turn to the inter-individual variations of human
genomes, which – with the introduction of microarray-based
techniques ten years ago – also came to the knowledge of sci-
entists in oncology research. These variations have to be con-
sidered when investigating tumor genomes by SNParray tech-
niques in order not to mix-up germline CNVs with tumor-
specific aberrations, i.e., copy number alterations (CNAs). CNVs
are deletions or duplications in the genome, occurring in non-
coding as well as in coding regions, which can vary consider-
ably in size, ranging from 50 base pairs to 3 megabases. The
causing events include non-allelic homologous recombination,
non-homologous end-joining, transposition of transposable ele-
ments or pseudogenes, and variable number of tandem repeats or
replication errors (24). The prevalence of CNVs in the human
genome is estimated to amount to 0.4% (25). Recent studies
suggest that the average human genome contains >1000 CNVs,
covering approximately four million base pairs (26, 27). SNPs
variations, on the other hand, are supposed to account for approx-
imately 0.1% of human genome inter-variability. Consequences
of CNVs include gene dose effects, with reduced or increased
protein expression, and also truncated protein sequences. While
most common CNVs have little or no role in causing diseases
(28), some have been associated with susceptibility or resistance
to diseases (29).
In case small gains or deletions are present in a tumor-derived
SNP profile, the database of genomic variation (DGV), which
currently contains over 100.000 published CNVs in the human
genome (24), can be helpful in the assignment of the varia-
tion/alteration. However, if an unequivocal assessment of the
copy number changes as either common variants or as tumor-
specific is necessary, analysis of constitutional DNA is imperative.
Furthermore, critical issues may arise if a change is clearly iden-
tified as a disease-associated CNV (constitutional) [the issue of
reporting and integrating CNV identification in medical reports
is addressed by the electronic medical record and genomics
(eMERGE) consortium (24)].
LOSS OF HETEROZYGOSITY AND UNIPARENTAL ISODISOMIES
So far, FISH, MLPA, and aCGH have been the main tools in
neuroblastoma diagnosis. Since these techniques give only infor-
mation on copy number changes, i.e., gains and losses, with-
out the possibility to infer the allele status (the only exception
being the detection of a monosomy, which definitely indicates the
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FIGURE 9 |The log2 copy number plot displays the structural variations
in theATRX gene. (A) Complete chromosome X with small deletion at
Xq21.1 visible in the zoomed-in chromosomal sub-band. The dots indicate the
log2 copy values of individual copy number probes. The intron–exon structure
of ATRX is shown in red (vertical bars are exons). (B) Five examples of ATRX
deletions spanning different parts of the gene are depicted (log2 ratio from
five neuroblastomas are shown in different colors analyzed with the ChAS
software).
presence of an LOH), cnLOHes, which may concern chromosomal
segments or whole chromosomes, have been beyond diagnostic
possibilities and therefore generally neglected in neuroblastoma
research/diagnosis.
PCR-based LOH techniques, on the other hand, have only been
applied for some selected chromosomal regions (e.g., 1p36.33)
leading to sometimes misleading results due to, e.g., constitutional
segmental UPD. Thus, one of the merits of SNP arrays is the detec-
tion of acquired (tumor-specific) cnLOHes whose frequency has
always been underestimated. Acquired whole chromosome uni-
parental somies reflect the presence of identical chromosomes,
which are not necessarily disomic, but occur also, especially in
neuroblastoma, in the case of trisomies and tetrasomies (theoret-
ically, all possible somy numbers can occur in combination with a
total LOH).
Originally, the term “uniparental disomy” was introduced by
Engel in 1980 (30) in the context of atypical diploid zygotes.
According to his concept, they can arise from the fusion of
nullisomic with normal monosomic gametes (with subsequent
monosomy rescue) or monosomic with disomic gametes (with
subsequent trisomy rescue). This kind of (inherited, not acquired
somatic) uniparental derivations of a certain chromosome can
then either be isodisomic (arisen from monosomy rescue, i.e.,
duplication) or heterodisomic (by trisomy rescue with loss of the
sole chromosome from the other parent). The latter uniparental
and heterodisomic situation would not be recognizable by the SNP
profile.
In case of whole chromosome somatic uniparental somies,
which are acquired during tumor evolution or progression, we
are always dealing with “isosomies,” which will be at the disomic,
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FIGURE 10 | Gives an example of a whole chromosome uniparental isodisomy. Both the log2 copy values and the smooth signal indicate two copies of
chromosome 11. However, only two allele peak tracks are visible representing the AA and BB alleles.
trisomic, or other somy levels (isodisomies, isotrisomies, and
isotetrasomies). The identity of the chromosomes is clearly recog-
nizable by the typical SNP profile reflecting LOH, i.e., the presence
of only two allele tracks. Mitotic errors with subsequent mono-
somy or trisomy rescues can be regarded as causative for this kind
of aberration. LCSH or ROH show the same SNP profile pattern
as described above, but are restricted to chromosomal segments.
They arise from somatic/mitotic recombinations (homologous
recombination) or double strand break repair and are not nec-
essarily acquired but can also be present constitutionally. If less
than 3 Mb in size, such LCSH are found in most individuals and
may total up to 2–5% of the genome (31). Even larger and multiple
LCSH up to 15Mbs are not necessarily tumor specific but may arise
from consanguinity. Thus, as already mentioned in the context of
small copy number changes, the investigation of constitutional
DNA is often necessary to clarify this issue.
WHOLE CHROMOSOME ABERRATIONS – TUMOR CELL PLOIDY AND
NEW TECHNIQUES TO DETERMINE AN “OLD PROGNOSTIC INDICATOR”
IN NEUROBLASTOMA
In neuroblastoma, evaluation of the tumor cell content is a long-
standing tradition (32). Due to its prognostic impact – two genetic
subtypes based on differences in the ploidy levels, which are
associated with age and prognosis as well – ploidy was quickly
implemented into risk-grouping schemes (e.g., INRG). On the
whole, a hyperdiploid (near-triploid or -penta-/-hexaploid) DNA
content slightly prevails (32, 33). Locoregional neuroblastomas are
commonly hyperdiploid. However, in ganglioneuroblastomas and
ganglioneuromas and possibly also in differentiating neuroblas-
tomas, the large amount of diploid Schwann cells can mask the
aneuploidy of the neuroblastoma cell population (see “UHD SNP
array results and pitfalls in case of spontaneous neuroblastoma
maturation and regression” section).
While exact DNA values can only be generated by FACS mea-
surements, SNP arrays give the somy numbers of all chromosomes
from which the DNA content can be deduced, provided the base-
line (see above) was correctly assigned to the disomic level. The
adapted Circos plot tool as described by Krzywinski et al. (34) is
a helpful tool to visualize these whole chromosome aberrations
(Figure 2).
Besides diploidy (di-tetraploidy), an aneuploid (near-triploid,
-pentaploid, -hexaploid) DNA content is commonly encountered
(15). The somy levels of the single chromosomes can vary from
di- to multisomic. Monosomies, however, are virtually never found
in neuroblastomas. Although near-triploid neuroblastomas have
been considered as almost consistently favorable tumors, they can,
as diploid neuroblastomas usually do, show segmental aberra-
tions and even oncogene amplifications. Original tumor ploidy
evaluations were based on classical cytogenetic approaches or
flow cytometric measurements. However, chromosome studies,
though potentially very informative, have different disadvantages
and therefore are not used in the clinical routine anymore. Flow
cytometry or static photometry are excellent tools for this purpose,
but cannot provide information on structural chromosome aber-
rations of the tumor cell population. Today, whole chromosome
gains or losses leading to changes in the ploidy level can elegantly
be recorded by pan-genomic techniques (CGH and SNParray)
with the great advantage that also information on structural aber-
rations, i.e., amplifications or typical or atypical SCAs can be
obtained simultaneously.
A number of studies have shown that in patients less than
18 months of age with metastatic disease, hyperdiploidy in com-
bination with a non-amplified MYCN gene, and a lack of specific
SCAs (such as 11q deletion) is commonly predictive of a favorable
outcome (10, 11, 35). However, despite the fact that tumor cell
hyperdiploidy (usually near-triploid DNA content) is frequently
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associated with spontaneous maturation (36) or spontaneous
regression (14,35), this ploidy level alone cannot guarantee a favor-
able tumor behavior. The long-standing view, that tumors with this
ploidy level almost always lack MNA and SCA, is a concept that
cannot be maintained anymore. It is estimated that at least 20%
of hyperdiploid tumors in localized stages and the vast major-
ity in metastatic stages (except for stage MS) contain structural
chromosome rearrangements, including MNA (Ambros, personal
observation), which lead to a clinically aggressive tumor behavior
(13, 14). As already mentioned above, the somy- (copy number
of individual chromosomes) and ploidy- (number of sets of chro-
mosomes in the nucleus) level can also be depicted on the basis
of SNParray data by a combined analysis of the copy number and
SNP data.
GENE AMPLIFICATIONS
Neuroblastomas with an unfavorable/aggressive clinical behavior
have a high tendency for locally invasive growth and widespread
metastatic dissemination via the lymphatic and hematogenous sys-
tems. Development of resistance to cytotoxic drugs during the
course of the disease is an important reason for treatment failure.
High-level amplification of the MYCN gene – besides a few other
amplified genes – is detected in 20–25% of neuroblastomas.MYCN
amplification has been shown to be strongly associated with rapid
tumor progression and poor prognosis in patients of all ages, inde-
pendent of the stage of disease (with the exception of stage 1) (5,
8, 9, 37). Frequently, adjacently located genes, like DDX1, NAG
(NBAS) or, more rarely, the proximally locatedALK gene (less fre-
quently involved), are co-amplified with MYCN (18). Recent data
indicate that information aboutALK amplification/mutation may
be of interest when looking for alternative treatment strategies
such as ALK inhibitors (38). In addition, genes located on chro-
mosome 12q, like MDM2 and CDK4 (which may be amplified in
the presence or absence of the MYCN gene), may indicate a sub-
set of tumors with a unique clinical behavior (own observation;
Martinsson, personal communication).
The occurrence of intratumor heterogeneity of MNA
(hetMNA) has been reported by different groups (39–41). In the
SNP array profile, the intensity peaks are less high when only a
sub-population of the cells carries the amplification, as exempli-
fied in the hetMNA tumor presented in here. Caveat: array data
per se are usually not sufficient to discriminate hetMNA from
homMNA. Low MYCN peaks can also be due to a high normal
cell content (e.g., after chemotherapy or caused by sampling error).
Therefore, I-FISH MYCN data should be generated in any case.
All in all, the clinical meaning of hetMNA is still unclear regarding
its effect on patients’ assignment to specific treatment strategies.
Therefore, a detailed analysis of a large number of hetMNA tumors
and a link with the clinical data is crucial. Although the presence
of homogenous amplification of the MYCN oncogene is central
to the risk stratification systems in virtually all cooperative clin-
ical trial groups, it is important to emphasize that the majority
of aggressively behaving neuroblastomas do not show amplifica-
tion of this oncogene. Thus, other genomic features are associated
with/responsible for aggressively growing tumors. In the follow-
ing, we describe the currently best-known genomic changes that
are associated with a clinically unfavorable behavior.
SEGMENTAL CHROMOSOMAL ABERRATIONS
SCAs, especially as the “typical” ones described above, have repeat-
edly been shown to be present in tumors with unfavorable behav-
ior. They manifest as losses or gains of larger chromosomal seg-
ments spanning from at least 3 Mb (by definition) to a complete
arm of a chromosome. Historically, deletions at the short arm
of chromosome 1, especially of the chromosomal region 1p36.3,
were among the first genomic aberrations described in neuroblas-
toma (33, 42). However, as this aberration is frequently associated
with MNA, it lost importance as prognostic marker. Conversely,
the deletion at the long arm of chromosome 11 (11q) has gained
importance over the last years, since these deletions occur predom-
inantly in tumors without MYCN amplification. The 11q deletion
has thus emerged as a powerful biomarker of outcome in addition
toMYCN amplification (43–45). Another prominent and very fre-
quently observed SCA, is the unbalanced gain of the long arm of
chromosome 17 (46–48). In addition, some studies have shown
that deletions at the chromosomal regions 3p, 4p, 9p, and 12p,
which do occur at low frequency, can have prognostic impact (35,
49, 50). Recent publications clearly demonstrate the potential of
genome-wide approaches to further refine the prognostic accuracy
of somatically acquired chromosomal alterations (18, 35, 51–54),
and numerous studies have demonstrated that in tumors without
MNA, SCAs are frequently associated with clinically aggressive
disease – for a summary see, e.g., Ref. (12). However, as already
briefly discussed, the influence of SCAs on tumor behavior can dif-
fer in different age groups. The genomic data from patients with
localized, resectable, tumors without MNA not receiving cytotoxic
treatment and enrolled in the LNESG 1 trial (Localized Neuroblas-
toma European Study Group 94.01) showed a strong prognostic
impact of SCAs in patients over 18 months at diagnosis which
could not be observed in younger patients (Ambros, personal
observation).
FROM THE DETECTION OF CHROMOTHRIPSIS TO GENE DELETIONS
All described aberrations presented below – from chromothripsis
to gene deletions, like ATRX, ARID1A and ARID1B genes – have,
so far, only been described by sequencing methods of the neu-
roblastoma genome. They can, however, also be detected by UHD
SNParray.
Chromothripsis
The recently described phenomenon named“chromothripsis”rep-
resents a shredding of single chromosomes or parts thereof and
subsequent random reassembly of the fragments. Molenaar and
co-workers describe this catastrophic event, which is significantly
associated with unfavorable prognosis, in 18% of high-stage neu-
roblastoma tumors (55). The breakpoints occurring in this aber-
ration can affect genes known to be involved in translocation
processes and, in addition, a chromothripsis chromosome can also
bear amplified regions.
According to the definition given by Korbel and Campbell, the
CNV between affected and non-affected chromosomal regions is
mostly limited to gains or losses of one copy (56). Even though
most studies describing chromothripsis applied whole genome
sequencing techniques, the use of the cost effective UHD SNParray
identified this peculiar genomic aberration without doubt.
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ATRX gene
A detailed study by Cheung and co-workers showed that mutations
affecting the X-chromosome-located ATRX gene were predomi-
nantly found in tumors from older children and adolescents, but
less frequently in younger children and not at all in tumors from
infants (0–18 months) (57). Mutations of theATRX gene are asso-
ciated with X-linked alpha thalassemia and mental retardation and
encode a subunit of the chromatin-remodeling complex involved
in H3.3 incorporation into heterochromatin at centromeric and
telomeric regions (58, 59). Similar to the study of Cheung and co-
workers, this aberration was exclusively found in patients older
than 18 months (mean age: 6.6 years, median: 4.7 years; range:
2.7–20 years) and was always associated with the ALT phenotype.
ARID1A and ARID1B
Among the genes not previously known to be involved in neu-
roblastoma, deletions and sequence alterations of the chromatin-
remodeling genes ARID1A and ARID1B were identified in 11%
(8 of 71 tumors), and these aberrations correlated with a more
aggressive phenotype (17). The SNParray technique used in this
study identified deletions affecting ARID1A in only one tumor
(data not shown).
UHD SNP ARRAY RESULTS AND PITFALLS IN CASE OF SPONTANEOUS
NEUROBLASTOMAMATURATION AND REGRESSION
Maturation not induced by cytotoxic therapy leads to the for-
mation of ganglioneuroblastomas (GNB) and ganglioneuromas
(GN) and is a prognostically favorable sign (with the exception
of a subgroup of nodular GNB). A gain of intact chromosomes
resulting in a rise of the DNA content in a near-triploid (-penta-
, -hexaploid) range (3, 10, 35, 36, 52) and absence of SCAs are
characteristic of the neuroblastic/ganglionic cell population in
Schwann cell stroma-rich tumors while the Schwann cell popu-
lation itself has a diploid DNA content (36, 60). Therefore, we
have concluded in previous work that Schwann cells in GN and
GNB are non-neoplastic, reactive cells that are attracted by neu-
roblastoma cells and we have always assumed that Schwann cells
play a crucial role in the maturation process by stopping tumor
cell growth and inducing differentiation of the neuroblastoma cells
(61). In terms of diagnostic measurement of the DNA content of
neuroblastomas, it is essential to know about the diploid Schwann
cell population in order not to ascribe a diploid DNA content
to the neuroblastoma cell population in case of a Schwann cell
stroma-rich tumor.
A favorable clinical behavior of neuroblastomas is typically
characterized by the capacity to undergo spontaneous regression
of a tumor residuum or, occasionally, of the complete tumor in
localized disease or even of metastasized tumors such as stage MS
(former stage 4S) tumors (5). The latter stage occurs in infants
up to the age of 18 months and is a unique form of disseminated
disease with the capacity of spontaneous regression in case of
favorable biological markers. These tumors almost always show
gains of whole chromosomes, mostly without SCAs and no gene
amplifications (13, 14).
GENETIC MARKERS CURRENTLY USED IN CLINICAL TRIALS
Because of the unique clinical/biological heterogeneity ranging
from a favorable behavior to very aggressive or indolent/chronic
disease and the association of genomic aberrations with the differ-
ent clinical manifestations, it soon became clear that to imple-
ment genomic information into the decision making process
was essential. As mentioned above, the MYCN status is used in
all current neuroblastoma clinical trials. The COG is using 11q
and ploidy information in addition to MYCN data to apply the
most appropriate therapeutic regimen. In Europe, a unique study,
the European Low and Intermediate Risk Neuroblastoma Study
(LINES), has recently started, implementing SCA data. In case
one or more of the seven typical SCAs are affected (i.e., losses at
1p, 3p, 4p, and 11q and gains at 1q, 2p, and 17q), an upstaging
in the treatment decision algorithm will be performed (Schleier-
macher G. and the SIOPEN Biology Group). This Europe-wide
treatment strategy employs real time online quality control of
the genomic data before the data are provided to the treating
clinician. Yet to allow all this to happen, certain prerequisites
had to be fulfilled. A number of technical and interpretation
guidelines have been published by the INRG Biology Group cov-
ering the following issues: Tumor sampling/storing/reporting of
the MYCN gene copy status, including analysis of heterogeneous
MYCN amplified tumors, and the evaluation and reporting of
SCAs (15).
CONCLUSION
In neuroblastoma patients, information on the genomic profile
of the tumor becomes an indispensable prerequisite for adequate
treatment planning. For on-going and future studies, the appli-
cation or implementation of technologies that provide a compre-
hensive picture of the tumor cell genome is essential. As shown
in this paper, high resolution SNParrays will allow new insights
into the genomic composition of tumors. To uncover the rela-
tively few known mutations in neuroblastomas, the combined use
of SNParray with, for example, targeted sequencing will be a useful
combination. In addition, FISH techniques to rapidly determine
the MYCN status at the cellular level and enabling the detec-
tion of intratumoral MYCN heterogeneity are expected to remain
in use in the diagnostic work up of neuroblastomas. Moreover,
it is anticipated that the rich genomic information on stage M
tumors which was published in the last few years will stimulate the
use of compounds targeting these recently described alterations.
Thus, genomic information is not only helpful for evidence-based
assignment of patients to specific treatment groups but will also
help to discern different types of stage M patients, enabling biology
based treatment options.
INFORMED CONSENT
As all patients were enrolled in clinical studies, informed consent
was obtained from all of them.
MATERIALS AND METHODS
DNA EXTRACTION SNParray ANALYSES
In order to obtain high quality SNParray data, we used DNA
extracted from fresh or fresh frozen tumor tissue with at least
30% tumor cell content or bone marrow samples applying the
“high salt” extraction technique (62). In case of BM samples, the
tumor cell fraction was either enriched by magnetic bead separa-
tion applying the antiGD2 antibody or extracted from cytospin
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slides or BM smears, the direct extraction was done only where
the percentage of disseminated tumor cells exceeded 30% (for fur-
ther details see, Abbasi et al., in submission), The Cytoscan HD
(Affymetrix, UK) platform was used in all experiments. This array
contains more than 1.9 million non-polymorphic markers and
over 740 thousand SNP markers with an average intragenic marker
spacing of 880 bps and intergenic marker spacing of 1737 bps. The
wet lab procedure and all other steps were done exactly according
to the manufacturer’s recommendations. Analysis of the SNPar-
ray data was done by the ChAS software (Affymetrix, UK) or for
comparison of larger number of samples with the Nexus software
(BioDiscovery, Hawthorne, CA, USA).
FISH
FISH experiments and documentation of the results were done as
described previously (63).
VISUALIZATION OF THE SNP ARRAY DATA APPLYING THE ChAS
SOFTWARE
The visualization tool of the software used in our institution
(ChAS) displays a karyoview screen where whole chromosome
and segmental chromosome gains and losses as well as LCSH and
LOHes can be highlighted (after selection of individual thresh-
olds). The detailed view contains all tracks with the copy number
and allele frequency information for each single chromosome sep-
arately. For the copy number probes different presentations can be
chosen, i.e., the log2 ratio, the weighted log2 ratio, the copy num-
ber state, and the so called smooth signal (Figures 3–5 and 8–10).
The allele information is depicted by the allele peaks. Further-
more, CNVs, copy number gains and losses, LCSHs and LOHes,
and the presence of mosaics can be highlighted also in the detailed
view (Figure S1 in Supplementary Material). The allele peaks – in
contrast to the visualization of the B-allele frequency – allow also
the recognition of gains and losses in addition to allele imbalances
and copy neutral and deletion-associated homozygosities. In addi-
tion, the genome can be analyzed at different levels of resolution
with exact assignment of breakpoints and identification of genes
included in amplicons.
CIRCOS PLOTS
Circos plots, as shown in Figures 1, 2, 6, and 7 and Figure S2 in
Supplementary Material, were created by extracting LRR and allele
peak information from ChAS-preprocessed Affymetrix.cychp-files
using Affymetrix Power Tools v1.15.2 and a custom Perl script.
Individual LRRs were binned into groups of 100 and the bin
average taken as smoothed LRR signal. Allele peaks were trans-
formed to BAFs with the formula (allele_peak – 250)/500 and
then trimmed to values between 0 and 1. Both smoothed LRRs
and BAFs were then plotted using the Circos software v0.64 (34).
LRR values≥ 0.15 are shown in blue (gain) and LRR values≤ -0.15
in red (loss).
ACKNOWLEDGMENTS
The research leading to these results has received funding from:
St. Anna Kinderkrebsforschung, Austrian National Bank, Grant
# 12473, the European Union’s Seventh Framework Program
(FP7/2007–2013) under the project ENCCA, grant agreement
HEALTH-F2-2011-261474. We are very grateful to Andrea Ziegler,
Diana Walder and Bettina Brunner-Herglotz for their excellent
technical assistance. Special thanks to Marion Zavadil M.Sc. for
critical reading the manuscript and Fikret Rifatbegovic M.Sc. for
technical help.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at http://www.frontiersin.org/journal/10.3389/fonc.2014.
00202/abstract
REFERENCES
1. Evans AE, Gerson J, Schnaufer L. Spontaneous regression of neuroblastoma.
Natl Cancer Inst Monogr (1976) 44:49–54.
2. D’Angio GJ, Evans AE, Koop CE. Special pattern of widespread neuroblastoma
with a favourable prognosis. Lancet (1971) 1(7708):1046–9. doi:10.1016/S0140-
6736(71)91606-0
3. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev
Cancer (2003) 3(3):203–16. doi:10.1038/nrc1014
4. Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet (2007)
369(9579):2106–20. doi:10.1016/S0140-6736(07)60983-0
5. Cohn SL, Pearson AD, London WB, Monclair T, Ambros PF, Brodeur GM, et al.
The International Neuroblastoma Risk Group (INRG) classification system: an
INRG Task Force report. J Clin Oncol (2009) 27(2):289–97. doi:10.1200/JCO.
2008.16.6785
6. Shimada H, Ambros IM, Dehner LP, Hata J, Joshi VV, Roald B, et al. The Inter-
national Neuroblastoma Pathology Classification (the Shimada system). Cancer
(1999) 86(2):364–72. doi:10.1002/(SICI)1097-0142(19990715)86:2<364::AID-
CNCR21>3.3.CO;2-Z
7. Shimada H, Chatten J, Newton-WA J, Sachs N, Hamoudi AB, Chiba T, et al.
Histopathologic prognostic factors in neuroblastic tumors: definition of sub-
types of ganglioneuroblastoma and an age-linked classification of neuroblas-
tomas. J Natl Cancer Inst (1984) 73(2):405–16.
8. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. Amplification of
N-myc in untreated human neuroblastomas correlates with advanced disease
stage. Science (1984) 224(4653):1121–4. doi:10.1126/science.6719137
9. Seeger RC, Brodeur GM, Sather H, Dalton A, Siegel SE, Wong KY, et al. Asso-
ciation of multiple copies of the N-myc oncogene with rapid progression of
neuroblastomas. N Engl J Med (1985) 313(18):1111–6.
10. Look AT, Hayes FA, Shuster JJ, Douglass EC, Castleberry RP, Bowman LC, et al.
Clinical relevance of tumor cell ploidy and N-myc gene amplification in child-
hood neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol (1991)
9(4):581–91.
11. Ladenstein R, Ambros IM, Potschger U, Amann G, Urban C, Fink FM, et al.
Prognostic significance of DNA di-tetraploidy in neuroblastoma. Med Pediatr
Oncol (2001) 36(1):83–92. doi:10.1002/1096-911X(20010101)36:1<83::AID-
MPO1020>3.0.CO;2-9
12. Schleiermacher G, Mosseri V, London WB, Maris JM, Brodeur GM, Attiyeh E,
et al. Segmental chromosomal alterations have prognostic impact in neurob-
lastoma: a report from the INRG project. Br J Cancer (2012) 107(8):1418–22.
doi:10.1038/bjc.2012.375
13. Janoueix-Lerosey I, Schleiermacher G, Michels E, Mosseri V, Ribeiro A, Lequin
D, et al. Overall genomic pattern is a predictor of outcome in neuroblastoma. J
Clin Oncol (2009) 27(7):1026–33. doi:10.1200/JCO.2008.16.0630
14. Ambros PF,Ambros IM, Strehl S, Bauer S, Luegmayr A, Kovar H, et al. Regression
and progression in neuroblastoma. Does genetics predict tumour behaviour?
Eur J Cancer (1995) 31A(4):510–5. doi:10.1016/0959-8049(95)00044-J
15. Ambros PF, Ambros IM, Brodeur GM, Haber M, Khan J, Nakagawara A, et al.
International consensus for neuroblastoma molecular diagnostics: report from
the International Neuroblastoma Risk Group (INRG) Biology Committee. Br J
Cancer (2009) 100(9):1471–82. doi:10.1038/sj.bjc.6605014
16. Pugh TJ, Morozova O, Attiyeh EF, Asgharzadeh S, Wei JS, Auclair D, et al. The
genetic landscape of high-risk neuroblastoma. Nat Genet (2013) 45(3):279–84.
doi:10.1038/ng.2529
17. Sausen M, Leary RJ, Jones S, Wu J, Reynolds CP, Liu X, et al. Integrated genomic
analyses identify ARID1A and ARID1B alterations in the childhood cancer neu-
roblastoma. Nat Genet (2012) 45(1):12–7. doi:10.1038/ng.2493
www.frontiersin.org August 2014 | Volume 4 | Article 202 | 15
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ambros et al. SNParray in neuroblastoma molecular diagnostics
18. George RE, Attiyeh EF, Li S, Moreau LA, Neuberg D, Li C, et al. Genome-wide
analysis of neuroblastomas using high-density single nucleotide polymorphism
arrays. PLoS One (2007) 2(2):e255. doi:10.1371/journal.pone.0000255
19. Lastowska M, Viprey V, Santibanez-Koref M, Wappler I, Peters H, Cullinane C,
et al. Identification of candidate genes involved in neuroblastoma progression
by combining genomic and expression microarrays with survival data.Oncogene
(2007) 26(53):7432–44.
20. Kryh H, Caren H, Erichsen J, Sjoberg RM, Abrahamsson J, Kogner P,
et al. Comprehensive SNP array study of frequently used neuroblastoma cell
lines; copy neutral loss of heterozygosity is common in the cell lines but uncom-
mon in primary tumors.BMCGenomics (2011) 12:443. doi:10.1186/1471-2164-
12-443
21. Souzaki R, Tajiri T, Teshiba R, Kinoshita Y, Yosue R, Kohashi K, et al. Correla-
tion between the number of segmental chromosome aberrations and the age
at diagnosis of diploid neuroblastomas without MYCN amplification. J Pediatr
Surg (2011) 46(12):2228–32. doi:10.1016/j.jpedsurg.2011.09.005
22. Conlin LK, Thiel BD, Bonnemann CG, Medne L, Ernst LM, Zackai EH,
et al. Mechanisms of mosaicism, chimerism and uniparental disomy identi-
fied by single nucleotide polymorphism array analysis. Hum Mol Genet (2010)
19(7):1263–75. doi:10.1093/hmg/ddq003
23. Thieme S, Groth P. Genome fusion detection: a novel method to detect fusion
genes from SNP-array data. Bioinformatics (2013) 29(6):671–7. doi:10.1093/
bioinformatics/btt028
24. Connolly JJ, Glessner JT, Almoguera B, Crosslin DR, Jarvik GP, Sleiman PM,
et al. Copy number variation analysis in the context of electronic medical
records and large-scale genomics consortium efforts. Front Genet (2014) 5:51.
doi:10.3389/fgene.2014.00051
25. Kidd JM, Cooper GM, Donahue WF, Hayden HS, Sampas N, Graves T, et al.
Mapping and sequencing of structural variation from eight human genomes.
Nature (2008) 453(7191):56–64. doi:10.1038/nature06862
26. Conrad DF, Pinto D, Redon R, Feuk L, Gokcumen O, Zhang Y, et al. Origins
and functional impact of copy number variation in the human genome. Nature
(2010) 464(7289):704–12. doi:10.1038/nature08516
27. Mills RE, Walter K, Stewart C, Handsaker RE, Chen K, Alkan C, et al. Mapping
copy number variation by population-scale genome sequencing. Nature (2011)
470(7332):59–65. doi:10.1038/nature09708
28. Wellcome Trust Case Control Consortium, Craddock N, Hurles ME, Cardin
N, Pearson RD, Plagnol V, et al. Genome-wide association study of CNVs in
16,000 cases of eight common diseases and 3,000 shared controls. Nature (2010)
464(7289):713–20. doi:10.1038/nature08979
29. Shlien A, Malkin D. Copy number variations and cancer susceptibility. Curr
Opin Oncol (2010) 22(1):55–63. doi:10.1097/CCO.0b013e328333dca4
30. Engel E. A new genetic concept: uniparental disomy and its potential effect,
isodisomy. Am J Med Genet (1980) 6(2):137–43. doi:10.1002/ajmg.1320060207
31. Rehder CW, David KL, Hirsch B, Toriello HV, Wilson CM, Kearney
HM. American College of Medical Genetics and Genomics: standards
and guidelines for documenting suspected consanguinity as an incidental
finding of genomic testing. Genet Med (2013) 15(2):150–2. doi:10.1038/gim.
2012.169
32. Look AT, Hayes FA, Nitschke R, McWilliams NB, Green AA. Cellular DNA
content as a predictor of response to chemotherapy in infants with unre-
sectable neuroblastoma. N Engl J Med (1984) 311(4):231–5. doi:10.1056/
NEJM198407263110405
33. Kaneko Y, Kanda N, Maseki N, Sakurai M, Tsuchida Y, Takeda T, et al. Differ-
ent karyotypic patterns in early and advanced stage neuroblastomas. Cancer Res
(1987) 47(1):311–8.
34. Krzywinski M, Schein J, Birol I, Connors J, Gascoyne R, Horsman D, et al. Cir-
cos: an information aesthetic for comparative genomics. Genome Res (2009)
19(9):1639–45. doi:10.1101/gr.092759.109
35. Schleiermacher G, Michon J, Huon I, d’Enghien CD, Klijanienko J, Brisse H,
et al. Chromosomal CGH identifies patients with a higher risk of relapse in
neuroblastoma without MYCN amplification. Br J Cancer (2007) 97(2):238–46.
doi:10.1038/sj.bjc.6603820
36. Ambros IM, Zellner A, Roald B, Amann G, Ladenstein R, Printz D, et al. Role of
ploidy, chromosome 1p, and Schwann cells in the maturation of neuroblastoma.
N Engl J Med (1996) 334(23):1505–11.
37. Perez CA, Matthay KK, Atkinson JB, Seeger RC, Shimada H, Haase GM, et al.
Biologic variables in the outcome of stages I and II neuroblastoma treated with
surgery as primary therapy: a children’s cancer group study. J Clin Oncol (2000)
18(1):18–26.
38. Carpenter EL, Mosse YP. Targeting ALK in neuroblastoma – preclinical and clini-
cal advancements.NatRevClinOncol (2012) 9(7):391–9. doi:10.1038/nrclinonc.
2012.72
39. Ambros PF, Ambros IM, Kerbl R, Luegmayr A, Rumpler S, Ladenstein R,
et al. Intratumoural heterogeneity of 1p deletions and MYCN amplification
in neuroblastomas. Med Pediatr Oncol (2001) 36(1):1–4. doi:10.1002/1096-
911X(20010101)36:1<1::AID-MPO1002>3.0.CO;2-L
40. Theissen J, Boensch M, Spitz R, Betts D, Stegmaier S, Christiansen H, et al. Het-
erogeneity of the MYCN oncogene in neuroblastoma. Clin Cancer Res (2009)
15(6):2085–90. doi:10.1158/1078-0432.CCR-08-1648
41. Villamon E, Berbegall AP, Piqueras M, Tadeo I, Castel V, Djos A, et al. Genetic
instability and intratumoral heterogeneity in neuroblastoma with MYCN ampli-
fication plus 11q deletion. PLoS One (2013) 8(1):e53740. doi:10.1371/journal.
pone.0053740
42. Brodeur GM, Green AA, Hayes FA, Williams KJ, Williams DL, Tsiatis AA. Cyto-
genetic features of human neuroblastomas and cell lines. Cancer Res (1981)
41(11 Pt 1):4678–86.
43. Attiyeh EF, London WB, Mosse YP, Wang Q, Winter C, Khazi D, et al. Chromo-
some 1p and 11q deletions and outcome in neuroblastoma. NEngl J Med (2005)
353(21):2243–53. doi:10.1056/NEJMoa052399
44. Maris JM, Guo C, White PS, Hogarty MD, Thompson PM, Stram DO, et al.
Allelic deletion at chromosome bands 11q14-23 is common in neuroblastoma.
Med Pediatr Oncol (2001) 36(1):24–7. doi:10.1002/1096-911X(20010101)36:
1<24::AID-MPO1007>3.0.CO;2-7
45. Caren H, Kryh H, Nethander M, Sjoberg RM, Trager C, Nilsson S, et al. High-risk
neuroblastoma tumors with 11q-deletion display a poor prognostic, chromo-
some instability phenotype with later onset. Proc Natl Acad Sci U S A (2010)
107(9):4323–8. doi:10.1073/pnas.0910684107
46. Caron H. Allelic loss of chromosome 1 and additional chromosome 17 material
are both unfavourable prognostic markers in neuroblastoma. Med Pediatr Oncol
(1995) 24(4):215–21. doi:10.1002/mpo.2950240402
47. Bown N, Cotterill S, Lastowska M, O’Neill S, Pearson AD, Plantaz D, et al.
Gain of chromosome arm 17q and adverse outcome in patients with neurob-
lastoma [see comments]. N Engl J Med (1999) 340(25):1954–61. doi:10.1056/
NEJM199906243402504
48. Spitz R, Hero B, Ernestus K, Berthold F. Gain of distal chromosome arm 17q is
not associated with poor prognosis in neuroblastoma. Clin Cancer Res (2003)
9(13):4835–40.
49. Caron H,van Sluis P,Buschman R,Pereira-do TR,Maes P,Beks L,et al. Allelic loss
of the short arm of chromosome 4 in neuroblastoma suggests a novel tumour
suppressor gene locus. Hum Genet (1996) 97(6):834–7. doi:10.1007/
BF02346199
50. Thompson PM, Maris JM, Hogarty MD, Seeger RC, Reynolds CP, Brodeur GM,
et al. Homozygous deletion of CDKN2A (p16INK4a/p14ARF) but not within
1p36 or at other tumor suppressor loci in neuroblastoma. Cancer Res (2001)
61(2):679–86.
51. Vandesompele J, Baudis M, De Preter K, Van Roy N, Ambros P, Bown N, et al.
Unequivocal delineation of clinicogenetic subgroups and development of a new
model for improved outcome prediction in neuroblastoma. J Clin Oncol (2005)
23(10):2280–99. doi:10.1200/JCO.2005.06.104
52. Mosse YP, Diskin SJ, Wasserman N, Rinaldi K, Attiyeh EF, Cole K, et al. Neurob-
lastomas have distinct genomic DNA profiles that predict clinical phenotype and
regional gene expression. Genes Chromosomes Cancer (2007) 46(10):936–49.
doi:10.1002/gcc.20477
53. Michels E, Vandesompele J, De Preter K, Hoebeeck J, Vermeulen J, Schramm
A, et al. ArrayCGH-based classification of neuroblastoma into genomic
subgroups. Genes Chromosomes Cancer (2007) 46(12):1098–108. doi:10.1002/
gcc.20496
54. Tomioka N, Oba S, Ohira M, Misra A, Fridlyand J, Ishii S, et al. Novel risk strat-
ification of patients with neuroblastoma by genomic signature, which is inde-
pendent of molecular signature. Oncogene (2008) 27(4):441–9. doi:10.1038/sj.
onc.1210661
55. Molenaar JJ, Koster J, Zwijnenburg DA, van Sluis P, Valentijn LJ, van der
Ploeg I, et al. Sequencing of neuroblastoma identifies chromothripsis and
defects in neuritogenesis genes. Nature (2012) 483(7391):589–93. doi:10.1038/
nature10910
Frontiers in Oncology | Pediatric Oncology August 2014 | Volume 4 | Article 202 | 16
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ambros et al. SNParray in neuroblastoma molecular diagnostics
56. Korbel JO, Campbell PJ. Criteria for inference of chromothripsis in cancer
genomes. Cell (2013) 152(6):1226–36. doi:10.1016/j.cell.2013.02.023
57. Cheung NK, Zhang J, Lu C, Parker M, Bahrami A, Tickoo SK, et al. Association
of age at diagnosis and genetic mutations in patients with neuroblastoma. JAMA
(2012) 307(10):1062–71. doi:10.1001/jama.2012.228
58. Gibbons R. Alpha thalassaemia-mental retardation, X linked. Orphanet J Rare
Dis (2006) 1:15. doi:10.1186/1750-1172-1-15
59. De La Fuente R, Baumann C, Viveiros MM. Role of ATRX in chromatin struc-
ture and function: implications for chromosome instability and human disease.
Reproduction (2011) 142(2):221–34. doi:10.1530/REP-10-0380
60. Bourdeaut F, Ribeiro A, Paris R, Pierron G, Couturier J, Peuchmaur M, et al. In
neuroblastic tumours, Schwann cells do not harbour the genetic alterations of
neuroblasts but may nevertheless share the same clonal origin. Oncogene (2008)
27(21):3066–71. doi:10.1038/sj.onc.1210965
61. Ambros IM, Attarbaschi A, Rumpler S, Luegmayr A, Turkof E, Gadner H, et al.
Neuroblastoma cells provoke Schwann cell proliferation in vitro. Med Pediatr
Oncol (2001) 36(1):163–8. doi:10.1002/1096-911X(20010101)36:1<163::AID-
MPO1040>3.3.CO;2-U
62. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extract-
ing DNA from human nucleated cells. Nucleic Acids Res (1988) 16(3):1215.
doi:10.1093/nar/16.3.1215
63. Narath R, Lorch T, Rudas M, Ambros PF. Automatic quantification of gene
amplification in clinical samples by IQ-FISH. Cytometry B Clin Cytom (2004)
57(1):15–22. doi:10.1002/cyto.b.10058
Conflict of Interest Statement: Affymetrix has paid for one congress visit in 2013
to Peter F. Ambros. The other co-authors declare that the research was conducted
in the absence of any commercial or financial relationships that could be construed
as a potential conflict of interest.
Received: 10 February 2014; accepted: 15 July 2014; published online: 12 August 2014.
Citation: Ambros IM, Brunner C, Abbasi R, Frech C and Ambros PF (2014) Ultra-
high density SNParray in neuroblastoma molecular diagnostics. Front. Oncol. 4:202.
doi: 10.3389/fonc.2014.00202
This article was submitted to Pediatric Oncology, a section of the journal Frontiers in
Oncology.
Copyright © 2014 Ambros, Brunner, Abbasi, Frech and Ambros. This is an open-access
article distributed under the terms of the Creative Commons Attribution License (CC
BY). The use, distribution or reproduction in other forums is permitted, provided the
original author(s) or licensor are credited and that the original publication in this
journal is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
www.frontiersin.org August 2014 | Volume 4 | Article 202 | 17
